Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception

January 19, 2017
With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism, has plenty of reasons for insomnia. Speaking at Biotech Showcase, List explained to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how he is also looking for assets designed to prevent, cure or even intercept the progression of key diseases such as obesity and NASH.
Previous Article
UK Establishment upbeat about Brexit’s effect on British life science industry
UK Establishment upbeat about Brexit’s effect on British life science industry

Brexit may no longer be at the top of popular news, but it continues to be a key concern for biopharma comp...

Next Video
Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta
Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta

Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 20...